TNT-i
TNT-i (NPD3064) is an inhibitor targeting M-Sec. TNT-i inhibits M-Sec-induced tunneling nanotube (TNT) formation reversibly. TNT-i reduces wild-type HIV-1 production in macrophages and M-Sec-expressing T cells. TNT-i shows low cytotoxic effects on macrophages and T cells. TNT-i can be used for the research of HIV-1 infection.
For research use only. We do not sell to patients.
- Formula: C18H25BrN2O2
- Molecular Weight:381.31
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
In Vitro
TNT-i (10 μM; 24 h) potently and reversibly inhibits M-Sec-induced TNT formation in GFP-M-Sec-transfected HeLa cells[1].
TNT-i (3-10 μM; 3 days) dose-dependently reduces TNT formation in wild-type HIV-1 JRFL-infected human monocyte-derived macrophages, with a 50% reduction observed after 3 days of incubation[1].
TNT-i (3-10 μM; 3 days) reduces wild-type HIV-1 production by approximately 50% in human monocyte-derived macrophages, with no effect on Nef-deficient HIV-1 production or MDM cell survival[1].
TNT-i (10 μM; 4 days) reduces wild-type HIV-1 production by approximately 50% in M-Sec-positive MT-2 T cells, with no effect on Nef-deficient HIV-1 production or MT-2 cell survival[1].
TNT-i (10 μM; 24 h) does not inhibit Nef-mediated downregulation of cell-surface CD4 or MHC I in 293-CD4 cells, indicating it does not target Nef's core regulatory functions[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
Appearance Solid
-
Molecular Weight 381.31
-
Formula C18H25BrN2O2
-
Color White to off-white
-
SMILES
CC[C@]1(C2)C[N@@](C(C3=CC(Br)=CC=C3O)[N@@]2C4)C[C@]4(CC)C1O
-
Synonyms
NPD3064
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)